CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $1 | $35 |
| % Growth | – | -100% | -97.5% | – |
| Cost of Goods Sold | $65 | $45 | $58 | $0 |
| Gross Profit | -$64 | -$45 | -$57 | $35 |
| % Margin | -7,177.1% | – | -6,548.4% | 100% |
| R&D Expenses | $59 | $166 | $72 | $82 |
| G&A Expenses | $17 | $19 | $19 | $18 |
| SG&A Expenses | $17 | $19 | $19 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$8 | -$1 | $0 | -$1 |
| Operating Expenses | $68 | $184 | $92 | $100 |
| Operating Income | -$132 | -$229 | -$148 | -$65 |
| % Margin | -14,854.8% | – | -17,158.8% | -184.5% |
| Other Income/Exp. Net | $26 | $22 | $14 | $28 |
| Pre-Tax Income | -$106 | -$207 | -$135 | -$37 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | -$106 | -$209 | -$136 | -$37 |
| % Margin | -11,973.1% | – | -15,722.1% | -106.6% |
| EPS | -1.17 | -2.4 | -1.58 | -0.44 |
| % Growth | 51.3% | -51.9% | -259.1% | – |
| EPS Diluted | -1.17 | -2.4 | -1.58 | -0.44 |
| Weighted Avg Shares Out | 91 | 87 | 86 | 85 |
| Weighted Avg Shares Out Dil | 91 | 87 | 86 | 85 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $5 | $5 | $5 |
| EBITDA | -$101 | -$225 | -$144 | -$60 |
| % Margin | -11,404.8% | – | -16,611.3% | -170.7% |